Pacific Biosciences of California Inc (PACB) Stock: A Year of Declines and Increases

A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Pacific Biosciences of California Inc’s current trading price is -76.56% away from its 52-week high, while its distance from the 52-week low is -1.30%. The stock’s price range for this time frame has been between $3.45 and $14.55. The trading volume of the company’s shares in the Healthcare reached around 7.97 million for the day, which was evidently lower than the average daily volume of 8.77 million over the last three months.

The stock market performance of Pacific Biosciences of California Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $14.55 on 07/18/23, while the lowest price during the same time frame was $3.45, recorded on 04/02/24.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


How Financial Performance Impacts Market Capitalization

Pacific Biosciences of California Inc (PACB) has experienced a quarterly decline of -65.24% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 913.71M and boasts a workforce of 796 employees.

The Role of Moving Averages and Trading Volume in Technical Analysis

Based on Barchart.com data, the company’s moving average over the 100-day period was 6.82, with a change in price of -3.39. Similarly, Pacific Biosciences of California Inc recorded 7,404,672 in trading volume during the last 100 days, posting a change of -49.85%.

How PACB’s Debt-to-Equity Ratio Affects Financial Health

A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 1.33. Similarly, the long-term debt-to-equity ratio is also 1.32.

PACB Stock Stochastic Average

The raw stochastic average for Pacific Biosciences of California Inc over the last 50 days is presently at 0.97%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 2.44%. Further, the company’s Stochastic %K and %D values for the last 20 days were 9.19% and 11.69%, respectively.

PACB Stock Price Performance Analysis

Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Year to date metric has recorded a loss of -65.24%.However, over the last six months, we can see a stronger performance of -59.16%. Over the last 30 days, the price of PACB has leaped by -34.30%. And in the last five days, it has fallen by -5.54%.

On Key

Related Posts